| Sheryll Chandler Coleman, PA | |
|
124 Little Fawn Ln, Alabaster, AL 35007-6410 | |
| (205) 620-0033 | |
| Not Available |
| Full Name | Sheryll Chandler Coleman |
|---|---|
| Gender | Female |
| Speciality | Physician Assistant - Surgical |
| Location | 124 Little Fawn Ln, Alabaster, Alabama |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205803251 | NPI | - | NPPES |
| 51519908COL | Other | AL | BLUE CROSS/BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363AS0400X | Physician Assistant - Surgical | PA008 (Alabama) | Primary |
| Entity Name | Urology Centers Of Alabama Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710962550 PECOS PAC ID: 0941264345 Enrollment ID: O20041116000389 |
News Archive
A team of scientists, led by the Institute of Food Research (IFR) in the UK, has discovered an immune system malfunction that is likely to play a profound role in food allergy.
The Royal Society has called on the United Nations to introduce a ban on human reproductive cloning at its 59th General Session in October.
Corium International, Inc., a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, announced today the pricing of its initial public offering of 6,500,000 shares of common stock at a price to the public of $8.00 per share.
22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction products, today announced that the U.S. Food & Drug Administration (FDA) has cleared an Investigational New Drug (IND) Application to conduct a Phase II-B clinical trial using X-22, a prescription smoking cessation aid in development.
› Verified 7 days ago
| Entity Name | Alabama Bone & Joint Clinic,llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780980540 PECOS PAC ID: 3678757739 Enrollment ID: O20110414000155 |
News Archive
A team of scientists, led by the Institute of Food Research (IFR) in the UK, has discovered an immune system malfunction that is likely to play a profound role in food allergy.
The Royal Society has called on the United Nations to introduce a ban on human reproductive cloning at its 59th General Session in October.
Corium International, Inc., a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, announced today the pricing of its initial public offering of 6,500,000 shares of common stock at a price to the public of $8.00 per share.
22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction products, today announced that the U.S. Food & Drug Administration (FDA) has cleared an Investigational New Drug (IND) Application to conduct a Phase II-B clinical trial using X-22, a prescription smoking cessation aid in development.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sheryll Chandler Coleman, PA 124 Little Fawn Ln, Alabaster, AL 35007-6410 Ph: (205) 620-0033 | Sheryll Chandler Coleman, PA 124 Little Fawn Ln, Alabaster, AL 35007-6410 Ph: (205) 620-0033 |
News Archive
A team of scientists, led by the Institute of Food Research (IFR) in the UK, has discovered an immune system malfunction that is likely to play a profound role in food allergy.
The Royal Society has called on the United Nations to introduce a ban on human reproductive cloning at its 59th General Session in October.
Corium International, Inc., a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, announced today the pricing of its initial public offering of 6,500,000 shares of common stock at a price to the public of $8.00 per share.
22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction products, today announced that the U.S. Food & Drug Administration (FDA) has cleared an Investigational New Drug (IND) Application to conduct a Phase II-B clinical trial using X-22, a prescription smoking cessation aid in development.
› Verified 7 days ago
Eva Helena Williams, PA-C Physician Assistant Medicare: May Accept Medicare Assignments Practice Location: 1004 1st St N Ste 270, Alabaster, AL 35007 Phone: 205-620-7523 | |
Mrs. Payton Patel, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 120 Colonial Promenade Pkwy, Alabaster, AL 35007 Phone: 205-605-0495 | |
Paige Kruse, PA-C Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 408 1st St N, Alabaster, AL 35007 Phone: 262-745-7455 | |
Kim Khanh Thi Ngo, PA Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 615 1st St N, Alabaster, AL 35007 Phone: 205-624-2100 | |
Mrs. Melanie Atkinson Sollenberger, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 1000 1st St N, Alabaster, AL 35007 Phone: 205-620-8547 | |
Miss Jessica Leigh Massey, P.A. Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 1216 1st St N, Alabaster, AL 35007 Phone: 205-664-4630 Fax: 205-664-4609 |